Wegovy HD 7.2 mg: Who Qualifies, Weight-Loss Results, Titration, and Cost
Approved in March 2026, the higher-dose Wegovy HD pen delivers 7.2 mg of semaglutide once weekly, helping select patients lose an extra 3 percentage points of body weight on average compared with the standard 2.4 mg dose. Learn whether you’re a candidate, how to move up safely, and what you’ll pay in today’s market.
Wegovy HD is a new 7.2 mg once-weekly semaglutide pen cleared by the FDA in March 2026 for adults who still have weight to lose or have regained weight on the 2.4 mg maintenance dose. In the STEP UP trial, patients who escalated to 7.2 mg lost an additional 3.1 percentage points of body weight versus those who stayed on 2.4 mg, without a major increase in serious side effects. The dose is rolled out gradually over 16 weeks, and cash prices average $399–$1,349 per month depending on assistance. Insurance coverage is expanding, including a $50 Medicare pilot starting July 2026.
- The FDA approved the 7.2 mg Wegovy HD pen on March 19, 2026, based on two phase 3b STEP UP studies. (fda.gov)
- Cash prices range from $399 per month through NovoCare’s self-pay program to a list price of roughly $1,349; prices will fall to $675 in 2027. (novocare.com)
- Medicare’s GLP-1 Bridge demonstration caps out-of-pocket costs at $50 per month for eligible Part D members from July 2026 through 2027. (cms.gov)
What Wegovy HD 7.2 mg Is - a higher GLP-1 dose for plateaus
Wegovy HD delivers three times the drug of the standard 2.4 mg pen, but it is still the same medication: semaglutide, a GLP-1 receptor agonist that curbs appetite and slows stomach emptying. The new strength comes in a prefilled, single-use pen that injects 7.2 mg in 0.75 mL subcutaneously once weekly. The FDA cleared it under a priority review after trials showed additional weight loss and cardiovascular-risk markers that continued to improve beyond what most users achieve at 2.4 mg. (fda.gov)
Semaglutide is… a synthetic analog of human glucagon-like peptide-1 that signals satiety centers in the brain, lowers the “set-point” weight, and reduces food noise. Unlike insulin, it does not cause hypoglycemia in people without diabetes.
Wegovy HD is brand-name Wegovy; there is no generic semaglutide 7.2 mg injection. If you see “compounded semaglutide 7.5 mg” offers online, verify the source carefully and read our guide on how to choose a safe GLP-1 provider.
Who Qualifies for Wegovy HD - stricter than the original label
The 7.2 mg strength is not a starting dose; candidates must meet FDA criteria and have already tried 2.4 mg for at least 12 weeks. According to the label, you may move up if:
- You have a body-mass index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with a weight-related condition (hypertension, dyslipidemia, OSA, pre-diabetes, or type 2 diabetes).
- You lost less than 15 % of baseline body weight after being stable on 2.4 mg for 3 months, or you regained ≥ 2 % of weight after an initial response.
- No contraindications emerged (personal/family medullary thyroid cancer, MEN-2, pancreatitis).
People with adequate weight loss on 2.4 mg or who struggle with GI side effects at lower doses are generally advised to stay at 2.4 mg.
How Much Additional Weight You Can Lose on 7.2 mg
Across two STEP UP phase 3b trials, average total weight loss reached 18.7 % of starting weight at 72 weeks for participants who escalated to 7.2 mg, versus 15.6 % for those maintained on 2.4 mg. That 3.1-point absolute difference matters: for a 300-lb (136-kg) patient, it translates to roughly 9 more pounds. (pubmed.ncbi.nlm.nih.gov)
| Outcome (Week 72) | 2.4 mg | 7.2 mg | Difference |
|---|---|---|---|
| Mean % weight change | -15.6 % | -18.7 % | -3.1 % |
| % reaching ≥ 20 % loss | 32 % | 48 % | +16 % |
| Waist-circumference change | -12.4 cm | -15.1 cm | -2.7 cm |
| Systolic BP reduction | -7 mm Hg | -9 mm Hg | -2 mm Hg |
Note: these figures are from the intention-to-treat analysis of STEP UP; individual results vary.
See if Wegovy HD is right for you
Book a video visit with a licensed U.S. provider today and find out whether you meet the criteria for the 7.2 mg dose and how much it will cost with your insurance.
How to Titrate Up Safely - the 16-week schedule
The FDA requires a gradual four-step escalation, adding no more than 0.5–1.8 mg every 4 weeks to minimize GI symptoms. Here is the recommended path once you are already stable at 2.4 mg:
| Week | Dose | Pen color | Tips |
|---|---|---|---|
| 0–4 | 2.4 mg | Blue | Maintain current dose, log side effects |
| 5–8 | 3.6 mg | Purple | Split meals, add anti-nausea plan |
| 9–12 | 4.8 mg | Teal | Stay hydrated, monitor heart rate |
| 13–16 | 6 mg | Orange | If tolerating well, move on schedule |
| 17 + | 7.2 mg (HD) | Red | Target maintenance dose |
Each weekly injection of Wegovy should be given on the same day and time; if you miss a dose by <48 hours, take it as soon as possible, otherwise skip it and resume the regular schedule. (dailymed.nlm.nih.gov)
For a deeper dive into timing your injections, bookmark our GLP-1 titration scheduling guide.
Side Effects and Safety - similar pattern, slightly higher rates
The safety profile of 7.2 mg mirrors lower doses, with mostly GI events that peak during dose escalation and decline after Week 20. In STEP UP T2D, 53 % of users reported nausea at 7.2 mg vs 51 % at 2.4 mg; serious adverse events occurred in 9.1 % vs 8.7 %, a non-significant difference. (pubmed.ncbi.nlm.nih.gov)
Common events: nausea, vomiting, diarrhea, constipation, abdominal pain, and injection-site reactions.
Less common, but notable: gallbladder disease, pancreatitis, increased heart rate, and new-onset or worsening diabetic retinopathy in patients with diabetes. Altered skin sensation (burning or prickling) has been reported more often at 7.2 mg. (fda.gov)
⚠️ Dose holds work
If GI symptoms become troublesome during escalation, your prescriber may keep you at the current dose for an extra 4 weeks before moving up, or may reduce you to the last tolerated dose.
Cost and Price Comparison - 7.2 mg vs 2.4 mg
The list price of Wegovy HD is the same as other pen strengths: $1,349 per month at U.S. retail pharmacies in mid-2026. But real-world prices diverge once savings cards, employer plans, and Medicare demos kick in.
| Scenario (July 2026) | 2.4 mg | 7.2 mg | Notes |
|---|---|---|---|
| List (WAC) | $1,349 | $1,349 | Price drop to $675 on Jan 1 2027 |
| NovoCare self-pay | $349 | $399 | After 2-dose intro offer |
| Commercial insurance, typical 30 % coinsurance | $405 | $405 | If on formulary |
| Medicare GLP-1 Bridge | $50 | $50 | Caps patient cost July 2026-Dec 2027 |
| Rx.com discount card | $875–$1,050 | $875–$1,050 | Varies by ZIP & chain |
Use Rx.com to compare prices-most patients pay ≤ $1,050 with a free discount card today, and prices will fall again when the official list price cuts in 2027. (prnewswire.com)
For a cost deep-dive, see our Wegovy cost guide.
Insurance and Medicare Coverage - expanding, but not universal
Commercial plans: About 56 % of large-group plans now cover at least one GLP-1 for weight management, and most update formularies quarterly. Because 7.2 mg shares the same NDC root as lower doses, prior authorizations usually carry over.
Medicare: The Medicare GLP-1 Bridge pilot (July 2026 – Dec 2027) caps Wegovy out-of-pocket costs at $50 per month for qualifying Part D beneficiaries who meet BMI criteria and complete lifestyle counseling. (cms.gov) Coverage applies equally to the 7.2 mg pen.
Medicaid & BALANCE model: Several states starting in 2026 have opted into CMS’s BALANCE model, allowing weight-loss GLP-1 coverage for adults with obesity. (cms.gov)
If your insurer denies coverage, ask your clinician for a tier-exception request or consider the $399 NovoCare self-pay option while appealing.
Tips to Maximize Success on Wegovy HD
Meal size and timing: Eat smaller, protein-forward meals every 4–5 hours to limit nausea and support lean mass.
Hydration: Aim for at least 80 oz (2.4 L) of water per day, plus electrolytes. See our electrolyte guide for options.
Activity: 150 minutes of moderate-intensity exercise weekly amplifies fat loss and preserves muscle.
Track side effects: Use the Rx.com app to log symptoms and share the PDF with your provider at follow-ups.
Should you request a move to Wegovy HD 7.2 mg?
Check the column that fits your situation:
✅ Stay on 2.4 mg
- You have lost ≥ 15 % of baseline weight
- BMI is now < 27 kg/m²
- Current dose is well tolerated
- No recent weight regain
🏥 Consider 7.2 mg
- Weight loss < 15 % after 3 months on 2.4 mg
- Weight regain ≥ 2 %
- Motivated to lose additional 5-10 lbs
- No GI intolerance at 2.4 mg
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe or persistent vomiting - risk of dehydration and electrolyte imbalance
- Severe abdominal pain radiating to back - possible pancreatitis
- Yellowing of skin or eyes - signs of gallstones or liver injury
- Rapid heartbeat (≥ 120 bpm at rest) - monitor for sustained tachycardia
- Lump or swelling in neck - rule out thyroid nodule
- Vision changes or floaters - diabetic retinopathy flare in patients with diabetes
- Thoughts of self-harm - call or text the Suicide & Crisis Lifeline at 988 (24/7)
- Allergic reaction - facial swelling, rash, or difficulty breathing
Scientific References
- U.S. Food and Drug Administration. FDA approves higher-dose Wegovy (semaglutide) injection for chronic weight management. 2026.
- Frias JP et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). NEJM. 2026.
- Rubino DM et al. Semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Diabetes Care. 2026.
- Centers for Medicare & Medicaid Services. CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries. 2026.
- DailyMed. Wegovy (semaglutide) injection, solution – Full Prescribing Information. Accessed 2026.
- Novo Nordisk. Company announces 2027 U.S. list-price reduction for Wegovy. 2026.
Frequently Asked Questions
Can I start Wegovy at 7.2 mg if I have never taken it before?
No. The 7.2 mg pen is designated for patients who have already titrated through the lower doses up to 2.4 mg. Starting at 7.2 mg would dramatically raise the risk of severe nausea and vomiting.
Does the 7.2 mg dose work faster than 2.4 mg?
Weight loss still follows a gradual curve; most of the extra benefit appears between Weeks 24 and 72. You will not see overnight changes, but you may continue losing weight after the standard dose plateaus.
Will the Wegovy HD coupon lower my copay?
Novo Nordisk’s Wegovy Savings Card applies to doses up to 7.2 mg for commercially insured patients whose plans cover the drug. Copays can drop to as low as $0 for 12 months, though most users see $25–$100 monthly out-of-pocket.
Is 7.2 mg safe for people with type 2 diabetes?
Yes, but blood-sugar lowering is dose-dependent, so prescribers may adjust other diabetes medications to avoid hypoglycemia. Monitor fasting and post-meal glucose closely in the first 12 weeks.
Can I alternate between 2.4 mg and 7.2 mg pens to save money?
Mix-and-match regimens are not studied and can lead to unpredictable side effects. If affordability is a concern, talk with your provider about delaying dose escalation or using patient-assistance programs.
Will weight come back if I drop back to 2.4 mg later?
Probably not immediately, but studies with lower GLP-1 doses show some regain once the medication is reduced. Maintain lifestyle measures-nutrition, exercise, sleep-to preserve your new set point.
Can I take anti-nausea medication every week during escalation?
Occasional use of ondansetron or prescription-strength promethazine is common, but routine weekly prophylaxis is not universally recommended. Discuss a personalized plan with your prescriber.
Take the Next Step Toward Your Goal Weight
Schedule an online visit to see whether Wegovy HD or another GLP-1 fits your plan, get a titration schedule, and unlock real-time pharmacy prices.
